Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Putter, H."'
Autor:
Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-De Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Group, TEAM Study Group
Publikováno v:
European Journal of Cancer, 95, 59-67
European Journal of Cancer, 95, 59-67. Elsevier Ltd.
European Journal of Cancer, 95, 59-67. Elsevier Ltd.
Background Extended endocrine therapy beyond 5 years for postmenopausal breast cancer has been studied within multiple phase III trials. Treatment compliance in these trials is generally poor. In this analysis, we aimed to determine factors that were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d486b65ea2eb3d71c07edc8efa8a0b64
https://hdl.handle.net/1887/95506
https://hdl.handle.net/1887/95506
Autor:
Charehbili, A., Hamdy, N.A.T., Smit, V.T.H.B.M., Kessels, L., Bochove, A. van, Laarhoven, H.W. van, Putter, H., Kranenbarg, E.M.K., Leeuwen-Stok, A.E. van, Hoeven, J.J.M. van der, Velde, C.J.H. van de, Nortier, J.W.R., Kroep, J.R., Dutch Breast Canc Res Grp BOOG
Publikováno v:
Breast, 25, pp. 69-74
The Breast, 25, 69-74
Breast (Edinburgh, Scotland), 25, 69-74. Churchill Livingstone
Breast, 25, 69-74
The Breast, 25, 69-74
Breast (Edinburgh, Scotland), 25, 69-74. Churchill Livingstone
Breast, 25, 69-74
Item does not contain fulltext BACKGROUND: Serum levels of 25-OH vitamin D3 (vitamin D) have been shown to be prognostic for disease-free survival in patients with breast cancer. We investigated the predictive value of these levels for pathological r
Autor:
Charehbili, A., Ven, S. van de, Smit, V.T.H.B.M., Kranenbarg, E.K., Hamdy, N.A.T., Putter, H., Heijns, J.B., Warmerdam, L.J.C. van, Kessels, L., Dercksen, M., Pepels, M.J., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Wasser, M.N., Leeuwen-Stok, A.E. van, Liefers, G.J., Velde, C.J.H. van de, Nortier, J.W.R., Kroep, J.R., Dutch Breast Canc Res Grp BOOG
Publikováno v:
Annals of Oncology, 25, 5, pp. 998-1004
Annals of Oncology, 25(5), 998-1004. Oxford University Press
Annals of oncology, 25(5), 998-1004. Oxford University Press
Annals of Oncology, 25(5), 998-1004
Annals of Oncology, 25, 998-1004
Annals of Oncology, 25(5), 998-1004. Oxford University Press
Annals of oncology, 25(5), 998-1004. Oxford University Press
Annals of Oncology, 25(5), 998-1004
Annals of Oncology, 25, 998-1004
Item does not contain fulltext BACKGROUND: The role of zoledronic acid (ZA) when added to the neoadjuvant treatment of breast cancer (BC) in enhancing the clinical and pathological response of tumors is unclear. The effect of ZA on the antitumor effe
Autor:
Nes, J.G.H. van, Putter, H., Hezewijk, M. van, Hille, E.T.M., Bartelink, H., Collette, L., Velde, C.J.H. van de, EORTC Breast Canc Grp
Publikováno v:
EJSO-European Journal of Surgical Oncology, 36(7), 617-624
Aims: After treatment, early breast cancer patients undergo follow-up according to standard regimens. After the first year, the main goal is particularly to detect locoregional recurrences (LRR). Our aim was to develop a simple prognostic index to pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21fa6e7496b8d92ea4c3255d3069b16
https://hdl.handle.net/1887/110226
https://hdl.handle.net/1887/110226